AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings

(RTTNews) - The US Food and Drug Administration approved AstraZeneca (AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 https://www.nasdaq.com/articles/azn-fda-approves-enhertu-her2-positive-early-breast-cancer-neoadjuvant-and-adjuvant